Two decades of Alzheimer's research may be based on deliberate fraud that has cost millions of lives

Last month, drug company Genentech reported on the first clinical trials of the drug crenezumab, a drug targeting amyloid proteins that form sticky plaques in the brains of Alzheimer’s disease patients. The drug had been particularly effective in...

Click to view the original at

Hasnain says:

How can these folks sleep at night? So much money wasted and much more importantly a misdirection of efforts away from things that could have saved so many lives.

“Over the last two decades, Alzheimer’s drugs have been notable mostly for having a 99% failure rate in human trials. It’s not unusual for drugs that are effective in vitro and in animal models to turn out to be less than successful when used in humans, but Alzheimer’s has a record that makes the batting average in other areas look like Hall of Fame material.

And now we have a good idea of why. Because it looks like the original paper that established the amyloid plaque model as the foundation of Alzheimer’s research over the last 16 years might not just be wrong, but a deliberate fraud.”

Posted on 2022-07-23T18:00:26+0000